A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)

INTRODUCTION: SB5 is an approved biosimilar of adalimumab, a monoclonal anti-tumor necrosis factor (anti-TNF) antibody. This study compared pharmacokinetics (PK), safety, tolerability, and immunogenicity between a new high-concentration, low-volume, and citrate-free formulation (40 mg/0.4 ml, SB5-HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, So-shin, Lee, Minkyung, Baek, Yumin, Lee, Sukho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309445/
https://www.ncbi.nlm.nih.gov/pubmed/35776269
http://dx.doi.org/10.1007/s40744-022-00471-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309445/
https://www.ncbi.nlm.nih.gov/pubmed/35776269
http://dx.doi.org/10.1007/s40744-022-00471-8

Ejemplares similares